Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease

Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease - Longevity Biotech Skip to main content Hit enter to search or ESC to close Close Search Newsroom Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease By kappNo Comments February 7, 2017 – Philadelphia, PA Longevity Biotech and University of Nebraska Medical center announce follow-on funding for the development of LBT-3627 as a novel therapeutic strategy for Parkinson’s disease. Privacy Policy  |  Cookies Policy  |  Terms & Conditions linkedin © 2026 Longevity Biotech. All Rights Reserved Close Menu ABOUT LONGEVITY BIOTECH About Us Leadership Team Board of Directors Scientific Advisors Careers SCIENTIFIC APPROACH Immune Rebalancing Precision Neuroscience Hybridtide™ Platform Publications PIPELINE LBT-3627 Pipeline CLINICAL TRIALS INVESTORS NEWSROOM CONTACT linkedin

The release as fetched from its publisher. longevitybiotech.com ↗